EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Limited, each of which is a separate legal entity. Ernst & Young Limited is a Swiss company with registered seats in Switzerland providing services to clients in Switzerland.
Select your location
Local sites
Life Sciences 4.0: securing value through data-driven platforms
Today, every company developing health care products and services is a data company, and therefore a technology company.
Increased customer expectations and rapid technological advances are disrupting the healthcare industry, causing power to shift across traditional stakeholder groups and creating opportunities for new entrants. As the data and algorithms that drive patient-centric health outcomes become the ultimate healthcare products, organizations that harness data-fueled insights will lead in this new industry paradigm.
With services structured around delivering a commercial edge and promoting intelligent automation in life sciences, we are well-positioned to explore the emerging platforms of care in the new health-outcomes-driven ecosystem. Explore our insights below.
Our latest thinking
Collaborative Care: The Role of Patient Data in Advancing AI in Healthcare
How to unlock AI’s potential in healthcare with patient-owned data
29 Oct 2024
Martin Blanke
The Unstoppables: Success stories of the world’s most inspiring entrepreneurs
The latest EY entrepreneurship documentary, “The Unstoppables 3,” features inspiring professional and personal entrepreneur success stories. Read more.
09 Apr 2024
Stasia Mitchell
What can we learn from the continuous glucose monitoring device market?
The continuous glucose monitoring (CGM) device market offers important lessons to diabetes medical device manufacturers on how to capture untapped market potential.
07 Mar 2024
Dr. Silvano Perrotta
Shaping the future of life sciences: AI‘s regulatory, risk and technology dimensions
EY’s whitepaper helps organizations navigate the complexities of AI to optimize performance and remain compliant.
19 Dec 2023
Alexei Koifman
Supply chain visibility strategic priority for pharma
With digitally driven end-to-end supply chain visibility, pharma companies will be better prepared for the next major supply chain disruption. Learn more.
04 Oct 2023
Derron Stark
If compensation is key, how do you unlock insights into market rates?
Salary reviews beyond simple benchmarks offer valuable insights into the remuneration practice of the market – and your own company.
23 Jun 2023
Radmilla Del Pozzo
Life Science Real Estate: The real estate asset class of the future
Resilient portfolio diversification through life science real estate – but what is behind this asset class?
14 Mar 2023
Erik Ganz
Direct to your inbox
Stay up to date with our latest insights.
How EY can help